Navigation Links
Heart screening unnecessary in type 2 diabetes patients with no symptoms
Date:4/14/2009

Routine screening for coronary artery disease in type 2 diabetes patients with no symptoms of angina or a history of coronary disease is unnecessary and may lead initially to more invasive and costly heart procedures, according to researchers at Yale School of Medicine. They report their findings in the April 15 Journal of the American Medical Association.

"Patients with type 2 diabetes with no symptoms who are feeling well can generally be managed effectively with preventive therapies such as lipid-lowering drugs, blood pressure medication, aspirin and diabetes treatment," said Lawrence Young, M.D., professor of medicine at Yale School of Medicine.

Coronary artery disease is a major cause of death and disability in patients with type 2 diabetes, who often undergo routine screening with stress testing. In this study, Young, Frans J. Wackers, M.D., Silvio Inzucchi, M.D., Deborah Chyun, and other colleagues sought to determine whether routinely screening diabetic patients without a history of heart problems helped identify those at higher cardiac risk.

The team spearheaded the Detection of Ischemia in Asymptomatic Diabetics study in which 1,123 participants were randomly assigned to either a screening stress test that looks at the blood flow to the heart, or to a group that received no screening. Participants enrolled at 14 centers in the United States and Canada and were evaluated over the next five years.

The team found that routine screening of type 2 diabetics identifies a small group of patients at higher risk, but does not significantly affect overall outcome. With each test costing about $1,000, and with 200 million patients with diabetes worldwide, Young says, "Routine screening would have tremendous economic implications and our findings did not indicate that routine stress testing had additional benefit in this population." The study also found that routine screening leads initially to more invasive procedures such as cardiac catheterization, stents or bypass.

"On the other hand, he cautioned, stress testing has an important role in evaluating patients with type 2 diabetes who have symptoms suggesting heart disease, since these individuals are at very high risk."

"This is a bit of good news in the field of diabetes where patients and their physicians have real concern for heart disease. In patients getting modern medical therapy in our study, serious heart problems were infrequent," said Young.


'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert

Related medicine news :

1. Drug for cluster headaches may cause heart problems
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. Restricting Blood Flow May Help Heart Bypass Patients
4. Urban Smog Tough on Young Adults Hearts
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Vitamin Es lack of heart benefit linked to dosage
7. Drug That Lowers Resting Heart Rate Being Tested
8. Heart Attack Boosts Diabetes Risk
9. Embryonic Stem Cells Repair Human Heart
10. U of M study: Early treatment can reverse heart damage
11. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... Advice Media, the industry leader in digital ... companies in North America and has been included in the Inc. 5000 for the second ... honored to be included in the Inc. 5000 rankings for the second year in a ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... ... August 16, 2017 , ... The next Patient Care ... accepted. , Students who successfully complete the seven-week long Patient Care Academy are ... (CNA). The average starting salary for a CNA in Kalamazoo is $24,428.* , As ...
(Date:8/16/2017)... ... August 16, 2017 , ... Greenfield Advisors is honored to be named to ... second year in a row. The Inc. 5000 list honors private businesses across the ... on the list once is a great accomplishment, but for us to be included ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Any Lab ... 5000. The company ranked #4429 on the newly released, 36th annual Inc. 5000 ... a unique look at the most successful companies within the American economy’s most dynamic ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
(Date:8/7/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO ... as president, effective Aug. 7, 2017. ... pursue other interests and will serve as president emeritus during ... served us in multiple leadership roles since he joined Diplomat ... and has provided decisive, strategic leadership which continues to benefit ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
Breaking Medicine Technology: